Status:

ACTIVE_NOT_RECRUITING

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Lead Sponsor:

UCB Biopharma SRL

Conditions:

Psoriatic Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).

Eligibility Criteria

Inclusion

  • In the opinion of the Investigator, the subject is expected to benefit from participation in this Open-Label Extension study
  • Subject completed PA0010 \[NCT03895203\] or PA0011 \[NCT03896581\] without meeting any withdrawal criteria
  • Female subjects must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception

Exclusion

  • Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of investigational medicinal product (IMP)
  • Subjects who meet any withdrawal criteria in PA0010 or PA0011. For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder studies, the Medical Monitor must be consulted prior to the subject's entry into PA0012, although the decision to enroll the subject remains with the Investigator
  • Subject has a positive or 2 indeterminate interferon gamma release assays (IGRAs) in one of the feeder studies, unless appropriately evaluated and treated

Key Trial Info

Start Date :

August 13 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 25 2026

Estimated Enrollment :

1131 Patients enrolled

Trial Details

Trial ID

NCT04009499

Start Date

August 13 2019

End Date

May 25 2026

Last Update

January 7 2026

Active Locations (138)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 35 (138 locations)

1

Pa0012 50017

Phoenix, Arizona, United States, 85037

2

Pa0012 50035

San Diego, California, United States, 92128

3

Pa0012 50033

Palm Harbor, Florida, United States, 34684

4

Pa0012 50037

Tampa, Florida, United States, 33613